Valuation: Zalicus Inc

Market Cap	7L 7L 6L 6L 10.51L 7.08Cr 10.69L 73.91L 29.06L 3.7Cr 28L 27.41L 12Cr	P/E 2014	-0.83x	P/E 2015	-1.35x
Enterprise Value	-1.59Cr -1.42Cr -1.32Cr -1.2Cr -2.25Cr -151.09Cr -2.28Cr -16Cr -6.21Cr -79Cr -5.98Cr -5.85Cr -252.43Cr	EV / Sales 2014	14,77,02,94,750x	EV / Sales 2015	8,36,58,631x
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

Latest news: Zalicus Inc

09/18/09	Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	CI
31/18/31	Praxis Precision Medicines, Inc. completed the acquisition of Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q).	CI
19/18/19	Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	CI
18/18/18	Praxis Precision Medicines, Inc. agreed to acquire Z944 assets from EPIRUS Biopharmaceuticals, Inc. (OTCPK:EPRS.Q) for $1 million.	CI
11/17/11	Notice of Intent of Asset Sale Filed by EPIRUS Biopharmaceuticals, Inc.	CI
19/16/19	Motion for Asset Sale Approved for EPIRUS Biopharmaceuticals, Inc.	CI
05/16/05	EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from S&P TMI Index	CI
03/16/03	EPIRUS Biopharmaceuticals, Inc.(OTCPK:EPRS.Q) dropped from NASDAQ Composite Index	CI
25/16/25	EPIRUS Biopharmaceuticals, Inc. Announces Management Resignations	CI
25/16/25	EPIRUS Biopharmaceuticals, Inc. Filed for Bankruptcy	CI
02/16/02	EPIRUS Biopharmaceuticals, Inc. Announces Executive Termination	CI
30/16/30	Polpharma S.A. completed the acquisition of EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc..	CI
14/16/14	Polpharma S.A. entered into a binding term sheet to acquire EPIRUS Biopharmaceuticals (Netherlands) B.V. from EPIRUS Biopharmaceuticals, Inc. for $3.5 million.	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+1.52%	-7.19%	+51.66%	+69.99%	6.58TCr
LONZA GROUP AG	+1.70%	+9.82%	+12.48%	+86.84%	5.19TCr
ARGENX SE	+3.92%	+5.48%	+3.84%	+67.22%	5.12TCr
IQVIA HOLDINGS INC.	+1.97%	+1.40%	+29.98%	+42.37%	4.38TCr
BEONE MEDICINES AG	+1.42%	+5.64%	+16.99%	+133.30%	4.21TCr
REVOLUTION MEDICINES, INC.	+0.80%	-6.08%	+236.69%	+528.10%	3.9TCr
CELLTRION, INC.	+2.16%	+9.87%	+18.92%	+59.70%	3.4TCr
WUXI BIOLOGICS (CAYMAN) INC.	+3.84%	-2.34%	+39.18%	+8.57%	2.52TCr
GENMAB A/S	+1.20%	+4.05%	+29.37%	+24.52%	2.28TCr
Average	+1.94%	+0.27%	+48.79%	+113.40%	4.18TCr
Weighted average by Cap.	+1.92%	+0.20%	+47.40%	+115.60%

	2014	2015
Net sales	0 0 0 0 0.01 0.38 0.01 0.04 0.02 0.2 0.02 0.01 0.63	0.7 0.62 0.58 0.53 0.99 66.46 1 6.94 2.73 34.74 2.63 2.58 111.04
Net income	-4.18Cr -3.73Cr -3.46Cr -3.14Cr -5.9Cr -396.72Cr -5.99Cr -41Cr -16Cr -207.35Cr -16Cr -15Cr -662.84Cr	-5.22Cr -4.65Cr -4.31Cr -3.92Cr -7.35Cr -494.79Cr -7.47Cr -52Cr -20Cr -258.61Cr -20Cr -19Cr -826.7Cr
Net Debt	-1.42Cr -1.26Cr -1.17Cr -1.06Cr -2Cr -134.44Cr -2.03Cr -14Cr -5.52Cr -70Cr -5.32Cr -5.21Cr -224.62Cr	-1.67Cr -1.49Cr -1.38Cr -1.25Cr -2.35Cr -158.16Cr -2.39Cr -17Cr -6.5Cr -83Cr -6.26Cr -6.13Cr -264.26Cr